NO20004250D0 - Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet - Google Patents

Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet

Info

Publication number
NO20004250D0
NO20004250D0 NO20004250A NO20004250A NO20004250D0 NO 20004250 D0 NO20004250 D0 NO 20004250D0 NO 20004250 A NO20004250 A NO 20004250A NO 20004250 A NO20004250 A NO 20004250A NO 20004250 D0 NO20004250 D0 NO 20004250D0
Authority
NO
Norway
Prior art keywords
tag
monoclonal antibodies
high affinity
humanized anti
affinity monoclonal
Prior art date
Application number
NO20004250A
Other languages
English (en)
Other versions
NO20004250L (no
Inventor
William Henry Kerr Anderson
Philip R Tempest
Frank J Carr
William J Harris
Kathryn Armour
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of NO20004250D0 publication Critical patent/NO20004250D0/no
Publication of NO20004250L publication Critical patent/NO20004250L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20004250A 1998-02-25 2000-08-24 Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet NO20004250L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003679 WO1999043816A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies

Publications (2)

Publication Number Publication Date
NO20004250D0 true NO20004250D0 (no) 2000-08-24
NO20004250L NO20004250L (no) 2000-10-24

Family

ID=22266462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004250A NO20004250L (no) 1998-02-25 2000-08-24 Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet

Country Status (9)

Country Link
EP (1) EP1056860B1 (no)
JP (1) JP4080692B2 (no)
AT (1) ATE288960T1 (no)
AU (1) AU758358B2 (no)
CA (1) CA2321932A1 (no)
DE (1) DE69829001T2 (no)
IL (1) IL138021A0 (no)
NO (1) NO20004250L (no)
WO (1) WO1999043816A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026394A1 (en) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants of humanized anti-carcinoma monoclonal antibody cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
KR100620554B1 (ko) * 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
WO2006116076A2 (en) * 2005-04-28 2006-11-02 Genencor International, Inc. Tab molecules
KR20130114758A (ko) * 2005-05-27 2013-10-17 오스페달레 산 라파엘 에스.알.엘. Mi-rna를 포함하는 유전자 벡터

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8907126A (pt) * 1988-10-19 1991-02-13 Dow Chemical Co Uma nova familia de anticorpos modificados,de elevada afinidade,para tratamento de cancer

Also Published As

Publication number Publication date
WO1999043816A1 (en) 1999-09-02
AU758358B2 (en) 2003-03-20
CA2321932A1 (en) 1999-09-02
EP1056860B1 (en) 2005-02-09
IL138021A0 (en) 2001-10-31
DE69829001D1 (de) 2005-03-17
JP2002504371A (ja) 2002-02-12
ATE288960T1 (de) 2005-02-15
JP4080692B2 (ja) 2008-04-23
DE69829001T2 (de) 2006-03-23
EP1056860A1 (en) 2000-12-06
NO20004250L (no) 2000-10-24
AU6439398A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
CY1113326T1 (el) Ανθρωπινα αντισωματα τα οποια δεσμευουν ανθρωπινη il-12 και μεθοδοι παραγωγης τους
IL165063A0 (en) An antibody or fragment thereof that binds to human insulin-like growth factor-I receptor
EA200800094A1 (ru) Антитела cd19 и их использование
HUP9901562A2 (hu) Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
SG170080A1 (en) Human monoclonal antibodies to o8e
RS80704A (en) ANTI- av?6.ANTIBODIES
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
IN2009KN02404A (no)
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE602006013029D1 (de) Anti-egfr-antikörper
UA99701C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
EP1708751A4 (en) METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
EA200601405A1 (ru) Гуманизированное антитело
WO2004060304A3 (en) Novel compositions and methods in cancer
WO2004058146A3 (en) Novel compositions and methods in cancer
WO2003064593A3 (en) Antigen panels and methods of using the same
NO20004250L (no) Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
WO2003080808A3 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application